Aldeyra Therapeutics, Inc. May 5, 2025 at 10:34 PM UTCMay 5May 5, 2025 at 10:34 PM UTC Original Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission The original announcement is unavailable.
